The effect of subthalamic nucleus deep brain stimulation on speech performance: a prospective clinical and tractography study.


Journal

Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000

Informations de publication

Date de publication:
16 Sep 2024
Historique:
received: 14 04 2024
accepted: 03 09 2024
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 16 9 2024
Statut: epublish

Résumé

Speech changes significantly impact the quality of life for Parkinson's disease (PD) patients. Deep Brain Stimulation (DBS) of the Subthalamic Nucleus (STN) is a standard treatment for advanced PD, but its effects on speech remain unclear. This study aimed to investigate the relationship between STN-DBS and speech changes in PD patients using comprehensive clinical assessments and tractography. Forty-seven PD patients underwent STN-DBS, with preoperative and 3-month postoperative assessments. Speech analyses included acoustic measurements, auditory-perceptual evaluations, and fluency-intelligibility tests. On the other hand, structures within the volume tissue activated (VTA) were identified using MRI and DTI. The clinical and demographic data and structures associated with VTA (Corticospinal tract, Internal capsule, Dentato-rubro-thalamic tract, Medial forebrain bundle, Medial lemniscus, Substantia nigra, Red nucleus) were compared with speech analyses. The majority of patients (36.2-55.4% good, 29.7-53.1% same) exhibited either improved or unchanged speech quality following STN-DBS. Only a small percentage (8.5-14.9%) experienced deterioration. Older patients and those with worsened motor symptoms postoperatively were more likely to experience negative speech changes (p < 0.05). Interestingly, stimulation of the right Substantia Nigra correlated with improved speech quality (p < 0.05). No significant relationship was found between other structures affected by VTA and speech changes. This study suggests that STN-DBS does not predominantly negatively impact speech in PD patients, with potential benefits observed, especially in younger patients. These findings underscore the importance of individualized treatment approaches and highlight the need for further long-term studies to optimize therapeutic outcomes and better understand the effects of STN-DBS on speech.

Sections du résumé

BACKGROUND BACKGROUND
Speech changes significantly impact the quality of life for Parkinson's disease (PD) patients. Deep Brain Stimulation (DBS) of the Subthalamic Nucleus (STN) is a standard treatment for advanced PD, but its effects on speech remain unclear. This study aimed to investigate the relationship between STN-DBS and speech changes in PD patients using comprehensive clinical assessments and tractography.
METHODS METHODS
Forty-seven PD patients underwent STN-DBS, with preoperative and 3-month postoperative assessments. Speech analyses included acoustic measurements, auditory-perceptual evaluations, and fluency-intelligibility tests. On the other hand, structures within the volume tissue activated (VTA) were identified using MRI and DTI. The clinical and demographic data and structures associated with VTA (Corticospinal tract, Internal capsule, Dentato-rubro-thalamic tract, Medial forebrain bundle, Medial lemniscus, Substantia nigra, Red nucleus) were compared with speech analyses.
RESULTS RESULTS
The majority of patients (36.2-55.4% good, 29.7-53.1% same) exhibited either improved or unchanged speech quality following STN-DBS. Only a small percentage (8.5-14.9%) experienced deterioration. Older patients and those with worsened motor symptoms postoperatively were more likely to experience negative speech changes (p < 0.05). Interestingly, stimulation of the right Substantia Nigra correlated with improved speech quality (p < 0.05). No significant relationship was found between other structures affected by VTA and speech changes.
CONCLUSIONS CONCLUSIONS
This study suggests that STN-DBS does not predominantly negatively impact speech in PD patients, with potential benefits observed, especially in younger patients. These findings underscore the importance of individualized treatment approaches and highlight the need for further long-term studies to optimize therapeutic outcomes and better understand the effects of STN-DBS on speech.

Identifiants

pubmed: 39283500
doi: 10.1007/s00701-024-06257-x
pii: 10.1007/s00701-024-06257-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

369

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Références

Aldridge D, Theodoros D, Angwin A, Vogel AP (2016) Speech outcomes in Parkinson’s disease after subthalamic nucleus deep brain stimulation: a systematic review. Parkinsonism Relat Disord 33:3–11
doi: 10.1016/j.parkreldis.2016.09.022 pubmed: 27693195
Anthofer JM, Steib K, Fellner C, Lange M, Brawanski A, Schlaier J (2015) DTI-based deterministic fibre tracking of the medial forebrain bundle. Acta Neurochir 157:469–477
doi: 10.1007/s00701-014-2335-y pubmed: 25585836
Bahners BH, Waterstraat G, Kannenberg S, Curio G, Schnitzler A, Nikulin V, Florin E (2022) Electrophysiological characterization of the hyperdirect pathway and its functional relevance for subthalamic deep brain stimulation. Exp Neurol 352:114031
doi: 10.1016/j.expneurol.2022.114031 pubmed: 35247373
Bobin M, Sulzer N, Bründler G, Staib M, Imbach LL, Stieglitz LH, Krauss P, Bichsel O, Baumann CR, Frühholz S (2024) Direct subthalamic nucleus stimulation influences speech and voice quality in Parkinson’s disease patients. Brain Stimul 17:112–124
doi: 10.1016/j.brs.2024.01.006 pubmed: 38272256
Chen Y, Ge S, Li Y, Li N, Wang J, Wang X, Li J, Jing J, Su M, Zheng Z (2018) Role of the cortico-subthalamic hyperdirect pathway in deep brain stimulation for the treatment of Parkinson disease: a diffusion tensor imaging study. World Neurosurg 114:e1079–e1085
doi: 10.1016/j.wneu.2018.03.149 pubmed: 29605702
Darley F (1975) L., Aronson, AE and Brown. JR: Motor Speech Disorders, Saunders Co
Darley FL, Aronson AE, Brown JR (1969) Clusters of deviant speech dimensions in the dysarthrias. J Speech Hear Res 12:462–496
doi: 10.1044/jshr.1203.462 pubmed: 5811846
Dashtipour K, Tafreshi A, Lee J, Crawley B (2018) Speech disorders in Parkinson’s disease: pathophysiology, medical management and surgical approaches. Neurodegenerative Disease Manage 8:337–348
doi: 10.2217/nmt-2018-0021
De Bodt MS, Wuyts FL, Van de Heyning PH, Croux C (1997) Test-retest study of the GRBAS scale: influence of experience and professional background on perceptual rating of voice quality. J Voice 11:74–80
doi: 10.1016/S0892-1997(97)80026-4 pubmed: 9075179
Deuschl G, Schüpbach M, Knudsen K, Pinsker MO, Cornu P, Rau J, Agid Y, Schade-Brittinger C (2013) Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson’s disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 19:56–61
doi: 10.1016/j.parkreldis.2012.07.004 pubmed: 22841616
Disease MDSTFoRSfPs (2003) The unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord 18:738–750
doi: 10.1002/mds.10473
Fenoy AJ, McHenry MA, Schiess MC (2016) Speech changes induced by deep brain stimulation of the subthalamic nucleus in Parkinson disease: involvement of the dentatorubrothalamic tract. J Neurosurg 126:2017–2027
doi: 10.3171/2016.5.JNS16243 pubmed: 27611200
Hoeppner J, Prudente-Morrissey L, Herpertz SC, Benecke R, Walter U (2009) Substantia Nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency. Eur Arch Psychiatry Clin NeuroSci 259:92–97
doi: 10.1007/s00406-008-0840-9 pubmed: 18806917
Jang SH, Kwon HG (2013) Anatomical location of the medial lemniscus and spinothalamic tract at the pons in the human brain: a diffusion tensor tractography study. Somatosens Motor Res 30:206–209
doi: 10.3109/08990220.2013.796923
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357
doi: 10.1093/ageing/26.5.353 pubmed: 9351479
Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G (2006) Subthalamic nucleus deep brain stimulation: summary and meta‐analysis of outcomes. Mov Disorders: Official J Mov Disorder Soc 21:S290–S304
doi: 10.1002/mds.20962
Kluin KJ, Gilman S, Foster NL, Sima AA, D’Amato CJ, Bruch LA, Bluemlein L, Little R, Johanns J (2001) Neuropathological correlates of dysarthria in progressive supranuclear palsy. Arch Neurol 58:265–269
doi: 10.1001/archneur.58.2.265 pubmed: 11176965
Kluin KJ, Mossner JM, Costello JT, Chou KL, Patil PG (2022) Motor speech effects in subthalamic deep brain stimulation for Parkinson’s disease. J Neurosurg 137:722–728
doi: 10.3171/2021.12.JNS211729 pubmed: 35090126
Lizarraga KJ, Jagid JR, Luca CC (2016) Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation on gait kinematics in Parkinson’s disease: a randomized, blinded study. J Neurol 263:1652–1656
doi: 10.1007/s00415-016-8191-3 pubmed: 27278062
Logemann JA, Fisher HB, Boshes B, Blonsky ER (1978) Frequency and cooccurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. J Speech Hear Disorders 43:47–57
doi: 10.1044/jshd.4301.47
Mahlknecht P, Akram H, Georgiev D, Tripoliti E, Candelario J, Zacharia A, Zrinzo L, Hyam J, Hariz M, Foltynie T (2017) Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson’s disease. Mov Disord 32:1174–1182
doi: 10.1002/mds.27042 pubmed: 28590508
Martin WE, Loewenson RB, Resch JA, Baker AB (1973) Parkinson’s disease: clinical analysis of 100 patients. Neurology 23:783–783
doi: 10.1212/WNL.23.8.783 pubmed: 4578348
Mori S, Crain BJ, Van Zijl PC (1998) 3D brain fiber reconstruction from diffusion MRI. NeuroImage 7:S710
doi: 10.1016/S1053-8119(18)31543-X
Murdoch BE (2004) Subcortical brain mechanisms in speech motor control. Speech motor control in normal and disordered speech, pp 139–174
Narayana S, Jacks A, Robin DA, Poizner H, Zhang W, Franklin C, Liotti M, Vogel D, Fox PT (2009) A noninvasive imaging approach to understanding speech changes following deep brain stimulation in Parkinson’s Disease.  Am J Speech Lang Pathol 18:146–161
Perestelo-Pérez L, Rivero-Santana A, Pérez-Ramos J, Serrano-Pérez P, Panetta J, Hilarion P (2014) Deep brain stimulation in Parkinson’s disease: meta-analysis of randomized controlled trials. J Neurol 261:2051–2060
doi: 10.1007/s00415-014-7254-6 pubmed: 24487826
Piboolnurak P, Lang AE, Lozano AM, Miyasaki JM, Saint-Cyr JA, Poon YYW, Hutchison WD, Dostrovsky JO, Moro E (2007) Levodopa response in long‐term bilateral subthalamic stimulation for Parkinson’s disease. Mov Disord 22:990–997
doi: 10.1002/mds.21482 pubmed: 17443692
Pinto S, Ozsancak C, Tripoliti E, Thobois S, Limousin-Dowsey P, Auzou P (2004) Treatments for dysarthria in Parkinson’s disease. Lancet Neurol 3:547–556
doi: 10.1016/S1474-4422(04)00854-3 pubmed: 15324723
Pinto S, Gentil M, Krack P, Sauleau P, Fraix V, Benabid AL, Pollak P (2005) Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech. Mov Disorders: Official J Mov Disorder Soc 20:1507–1515
doi: 10.1002/mds.20601
Rohl A, Gutierrez S, Johari K, Greenlee J, Tjaden K, Roberts A (2022) Speech dysfunction, cognition, and Parkinson’s disease. Prog Brain Res 269:153–173
doi: 10.1016/bs.pbr.2022.01.017 pubmed: 35248193 pmcid: 11321444
Samii A, Kelly VE, Slimp JC, Shumway-Cook A, Goodkin R (2007) Staged unilateral versus bilateral subthalamic nucleus stimulator implantation in Parkinson disease. Mov Disorders: Official J Mov Disorder Soc 22:1476–1481
doi: 10.1002/mds.21554
Skodda S, Rinsche H, Schlegel U (2009) Progression of dysprosody in Parkinson’s disease over time—a longitudinal study. Mov Disorders: Official J Mov Disorder Soc 24:716–722
doi: 10.1002/mds.22430
Tripoliti E, Zrinzo L, Martinez-Torres I, Frost E, Pinto S, Foltynie T, Holl E, Petersen E, Roughton M, Hariz M (2011) Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease. Neurology 76:80–86
doi: 10.1212/WNL.0b013e318203e7d0 pubmed: 21068426
van den Munckhof P, Bot M, Schuurman PR (2021) Targeting of the subthalamic nucleus in patients with Parkinson’s disease undergoing deep brain stimulation surgery. Neurol Therapy 10:61–73
doi: 10.1007/s40120-021-00233-8
Weaver F, Follett K, Hur K, Ippolito D, Stern M (2005) Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 103:956–967
doi: 10.3171/jns.2005.103.6.0956 pubmed: 16381181
Wodarg F, Herzog J, Reese R, Falk D, Pinsker MO, Steigerwald F, Jansen O, Deuschl G, Mehdorn HM, Volkmann J (2012) Stimulation site within the MRI-defined STN predicts postoperative motor outcome. Mov Disord 27:874–879
doi: 10.1002/mds.25006 pubmed: 22517070
Xie Y, Zhang Y, Zheng Z, Liu A, Wang X, Zhuang P, Li Y, Wang X (2011) Changes in speech characters of patients with Parkinson’s disease after bilateral subthalamic nucleus stimulation. J Voice 25:751–758
doi: 10.1016/j.jvoice.2010.08.002 pubmed: 21227642
Yasar O, Ozturk S, Kemal O, Kocabicak E (2022) Effects of Subthalamic Nucleus Deep Brain Stimulation surgery on Voice and Formant frequencies of vowels in Turkish. Turkish Neurosurg 32:764–772

Auteurs

Ozan Hasimoglu (O)

Basaksehir Cam and Sakura City Hospital, Neurosurgery, Istanbul, Turkey. ozanhasim@hotmail.com.

Ayca Altinkaya (A)

Basaksehir Cam and Sakura City Hospital, Neurology, Istanbul, Turkey.

Ozan Tuysuz (O)

Basaksehir Cam and Sakura City Hospital, Otorhinolaryngology, Istanbul, Turkey.

Taha Hanoglu (T)

Basaksehir Cam and Sakura City Hospital, Neurosurgery, Istanbul, Turkey.

Tuba Ozge Karacoban (TO)

Basaksehir Cam and Sakura City Hospital, Neurosurgery, Istanbul, Turkey.

Nur Bahar Geylan (NB)

Basaksehir Cam and Sakura City Hospital, Neurosurgery Nursing, Neuropsychiatry, Istanbul, Turkey.

Ozan Barut (O)

Bingöl State Hospital, Neurosurgery, Istanbul, Turkey.

Ridvan Basaran (R)

Basaksehir Cam and Sakura City Hospital, Speech and Language Therapy, Bingol, Turkey.

Buruc Erkan (B)

Basaksehir Cam and Sakura City Hospital, Neurosurgery, Istanbul, Turkey.

Oya Guclu (O)

Basaksehir Cam and Sakura City Hospital, Psychiatry, Istanbul, Turkey.

Ayhan Koksal (A)

Basaksehir Cam and Sakura City Hospital, Neurology, Istanbul, Turkey.

Burak Kocak (B)

Basaksehir Cam and Sakura City Hospital, Radiology, Istanbul, Turkey.

Bekir Tugcu (B)

Basaksehir Cam and Sakura City Hospital, Neurosurgery, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH